Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAV regimen in relapsed/refractory and newly diagnosed AML (real-world study)
ChiCTR2400091392Phase 4Not yet recruiting
- Sponsor
- General Hospital of the Northern Theater Command
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cladribine, cytarabine and venetoclax in acute myeloid leukemia (AML), sponsored by General Hospital of the Northern Theater Command. Primary endpoint: Composite complete remission rate (CRc: CR + CRi). Planned start Oct 2024; status: not yet recruiting.
02
Drugs
cladribinecytarabinevenetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2400091392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400091392.